Neuroma Management

Microscopic Structure

• Axons: Disorganized, entangled sprouts (Zuckerandl's spirals).
• Stroma: Dense fibrosis and scar tissue.
• Schwann Cells: Proliferating without guidance.

The connective tissue barrier prevents axons from advancing, causing them to turn back on themselves.

Neurophysiology of Pain

• Ectopic Pacemakers: Upregulation of Sodium Channels (Nav 1.3, 1.7, 1.8) at the nerve tip.
• Mechanosensitivity: The sprout becomes sensitive to pressure (Tinel's).
• Central Sensitization: Constant bombardment of the dorsal horn leads to chronic pain changes.

This explains why peripheral blocks sometimes fail in chronic cases (centralization).

Terminal Neuroma

• End of a cut nerve. Classic "stump" neuroma.
• Pathophysiology: Unchecked sprout formation.
• Example: Amputation stump neuroma.

This is the most common type encountered in clinical practice.

Neuroma-in-Continuity

• Intact perineurium/epineurium but internal damage.
• Axons are disrupted but the tube is intact.
• Often follows crush injury or partial laceration.

The challenge is determining if the axons are conducting through the scar.

Amputation Neuroma

• A form of terminal neuroma specifically at an amputation stump.
• Often mixed with scar tissue.
• High association with phantom limb pain.

Often involves multiple nerves (e.g., sciatic, saphenous) in the same stump.

Diagnostic Nerve Block

• Gold Standard.
• Inject Lidocaine proximal to the neuroma.
• Result: Complete relief of pain confirms peripheral generator.
• No Relief: Suggests central pain (Phantom) or wrong diagnosis.

Always use a control (saline) if psychogenic cause suspect (Placebo test).

Ultrasound / MRI

• Ultrasound: Can visualize the bulbous nerve end and its relationship to instability/scar.
• MRI: Useful for deep neuromas (e.g., Sciatic) or to rule out other pathology.

MR Neurography sequences are increasingly sensitive.

Level 1: Non-Surgical

• Desensitization: Massage, texture rubbing.
• Medication: Gabapentin, Pregabalin, Amitriptyline.
• Therapy: Mirror therapy (for Phantom pain).

Pharmacological management is the first line for neuropathic pain.

Level 2: Simple Surgery

• Resect and Bury: Cut the nerve back to healthy tissue and bury deep in muscle or bone.
• Failure Rate: High (20-30% recurrence). The nerve just grows another neuroma.

Doing the same thing and expecting a different result is madness.

Level 3: Physiological Reconstruction

• RPNI: Give the nerve a "dummy" muscle target.
• TMR: Transfer the nerve to a "real" muscle target.
• Centro-central: Connect two nerve ends together (Loop).

These techniques provide a "Stop Signal" to regenerating axons.

Regenerative Peripheral Nerve Interface (RPNI)

• Concept: Provide a physiologic target for the nerve end.
• Technique:
  1. Harvest a free muscle graft (e.g., Vastus Lateralis or local muscle). Size: 3x1.5cm.
  2. Neurolyse the nerve end.
  3. Wrap the muscle graft around the nerve end like a "Hot Dog in a Bun".
  4. Secure with sutures.
  5. Ensure the graft is well-vascularized by the recipient bed.
  6. Do not wrap too tightly (risk of ischemia).
• Outcome: Axons grow into the muscle graft and stop (Reinnervation).

The muscle acts as a "sponge" for regenerating axons. This prevents the formation of a chaotic neuroma bulb.

Targeted Muscle Reinnervation (TMR)

• Concept: Transfer the mixed nerve to a motor branch of a nearby muscle.
• Technique:
  1. Identify the painful nerve (Donor).
  2. Identify a motor branch to a redundant muscle (Recipient).
  3. Coapt nerve-to-nerve.
  4. Use fibrin glue or nylon sutures.
  5. Resect the neuroma bulb proximally to healthy fascicles.
• Outcome: Provides extensive target for regeneration. Also allows for myoelectric prosthesis control.

Originally designed for prosthetics, TMR is now a primary pain surgery. It "gives the nerve something to do/innervate".

Neuroma-in-Continuity

• Assessment: Intra-operative Nerve Action Potential (NAP).
• Results:
  • NAP Present: Neurolysis only. Do not cut.
  • No NAP: Resect and Graft (or Transfer).

NAPs are the only way to objectively assess function intra-operatively.

Recurrence

• Rate: High with simple excision. Reduced to greater than 10 percent with RPNI/TMR.
• Cause: Nerve grows out of the burial site or forms a new neuroma at the cut end.

Recurrence is frustrating for both surgeon and patient.

Chronic Pain

• CRPS: Surgery may trigger CRPS.
• Phantom Pain: Excision of stump neuroma may improve phantom pain (by reducing afferent barrage), but essentially treats a different pathology.

Do not promise a cure for phantom pain with simple neuroma excision.

Phantom pain is a cortical phenomenon (homunculus reorganization). Peripheral surgery only removes the trigger, not the memory.

Success Rates by Technique

• Simple Excision: Approximately 60-70% success rate. However, recurrence at the new transection site is common.
• Burial (Muscle/Bone): Approximately 70-80% success rate. Results depend heavily on the location and quality of the burial site.
• RPNI (Regenerative Peripheral Nerve Interface): Early data suggests over 90% success in reducing neuroma pain. The muscle graft provides a physiological target.
• TMR (Targeted Muscle Reinnervation): Over 90% success rate. Level II evidence from Dumanian trial supports its use.

Complete pain freedom is rare. The realistic goal is "manageable pain" allowing return to function.

Prognostic Factors

Favorable:

• Isolated peripheral neuroma without central sensitization.
• Complete pain relief with diagnostic nerve block.
• Short duration of symptoms (under 12 months).
• Absence of psychological comorbidities.
• Single neuroma rather than multiple.

Unfavorable:

• Incomplete relief with diagnostic block (suggests centralization).
• Duration over 2 years with established chronic pain behavior.
• Associated CRPS features.
• Concurrent phantom limb pain (requires separate treatment).
• Multiple previous failed surgeries.
• Significant litigation or compensation involvement.

Patient selection is critical. Operating on the wrong patient makes things worse.